Pangaea Oncology SA
MAD:PANG
Pangaea Oncology SA
MAD:PANG
Price:
1.65
EUR
Market Closed
Market Cap:
€56.8m
Relative Value
The Relative Value of one
PANG
stock under the Base Case scenario is
1.68
EUR.
Compared to the current market price of 1.65 EUR,
Pangaea Oncology SA
is
Undervalued by 2%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PANG
Relative Value
Base Case
1.68
EUR
Undervaluation 2%
Multiples Across Competitors
PANG Competitors Multiples
Pangaea Oncology SA Competitors
Pangaea Oncology SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| ES |
|
Pangaea Oncology SA
MAD:PANG
|
56.3m EUR | 3.8 | -44.7 | 121.9 | -25.1 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD | 375.4 | 4 444.8 | 1 409.2 | 3 011 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
191.7B USD | 4.3 | 28.7 | 20 | 26.9 | |
| US |
|
Danaher Corp
NYSE:DHR
|
148.4B USD | 6.1 | 41.2 | 22.8 | 34.7 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
79.2T KRW | 8.4 | 29 | 29.1 | 38.8 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
36.8B CHF | 5.7 | 39.3 | 28.8 | 28.8 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
291.5B CNY | 6.6 | 19.4 | 19.7 | 19.7 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.7B USD | 5 | 26.6 | 19.4 | 23 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.2B USD | 1.7 | 20.6 | 11.6 | 17.4 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.1B USD | 7 | 32.3 | 23.8 | 26.5 | |
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
164.6B HKD | 7.3 | 34.7 | 24.4 | 24.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
